Cencora (COR) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

04.02.26 15:30 Uhr

Werte in diesem Artikel
Aktien

301,80 EUR -3,05 EUR -1,00%

Indizes

6.896,9 PKT -20,9 PKT -0,30%

For the quarter ended December 2025, Cencora (COR) reported revenue of $85.93 billion, up 5.5% over the same period last year. EPS came in at $4.08, compared to $3.73 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $85.97 billion, representing a surprise of -0.04%. The company delivered an EPS surprise of +0.35%, with the consensus EPS estimate being $4.07.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Cencora performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenue- Total U.S. Healthcare Solutions: $76.21 billion versus the four-analyst average estimate of $76.72 billion. The reported number represents a year-over-year change of +2.9%.Revenue- Total International Healthcare Solutions: $7.62 billion compared to the $7.45 billion average estimate based on four analysts. The reported number represents a change of +2.2% year over year.Revenue- Intersegment eliminations: $-32.73 million versus $-29.74 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +860.1% change.View all Key Company Metrics for Cencora here>>>Shares of Cencora have returned +4.5% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Free Report: Profiting from the 2nd Wave of AI ExplosionThe next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.Investors who bought shares like Nvidia at the right time have had a shot at huge gains.But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.Access AI Boom 2.0 now, absolutely free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Cencora und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Cencora

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Cencora

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Cencora

Wer­bung

Analysen zu Cencora

DatumRatingAnalyst
20.07.2018AmerisourceBergen NeutralRobert W. Baird & Co. Incorporated
08.03.2018AmerisourceBergen Equal WeightBarclays Capital
08.02.2018AmerisourceBergen BuyNeedham & Company, LLC
30.01.2018AmerisourceBergen BuyNeedham & Company, LLC
23.01.2018AmerisourceBergen BuyNeedham & Company, LLC
DatumRatingAnalyst
08.02.2018AmerisourceBergen BuyNeedham & Company, LLC
30.01.2018AmerisourceBergen BuyNeedham & Company, LLC
23.01.2018AmerisourceBergen BuyNeedham & Company, LLC
04.12.2017AmerisourceBergen BuyDeutsche Bank AG
22.11.2017AmerisourceBergen BuyNeedham & Company, LLC
DatumRatingAnalyst
20.07.2018AmerisourceBergen NeutralRobert W. Baird & Co. Incorporated
08.03.2018AmerisourceBergen Equal WeightBarclays Capital
19.09.2017AmerisourceBergen Sector PerformRBC Capital Markets
04.08.2017AmerisourceBergen NeutralUBS AG
30.05.2017AmerisourceBergen NeutralMizuho
DatumRatingAnalyst
14.05.2007AmerisourceBergen reduceUBS

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Cencora nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen